PFIZER2023-01-012023-03-31 PFIZER2023-01-012023-03-31 PFIZER2023-01-012023-03-31in-bse-fin:OneOperatingExpenses01Member PFIZER2023-01-012023-03-31in-bse-fin:FourOperatingExpenses01Member PFIZER2023-03-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 500680 PFIZER NA Pfizer Limited Equity 2022-04-01 2023-03-31 2023-05-15 2023-05-05 INR Crores Yearly 15:00:00 17:45:00 2023-05-15 2023-05-15 true Cash Flow Indirect Declaration of unmodified opinion Single segment Pharmaceutical 2023-01-01 2023-03-31 Audited Standalone 5726400000.00 313800000.00 6040200000.00 706700000.00 1509600000.00 -56200000.00 653100000.00 25300000.00 264100000.00 1094500000.00 4197100000.00 1843100000.00 -195900000.00 1647200000.00 664300000.00 -313600000.00 350700000.00 0.00 1296500000.00 0.00 0.00 0.00 0.00 1296500000.00 41900000.00 1338400000.00 0.00 0.00 457500000.00 10 28.34 28.34 0.00 0.00 28.34 28.34 1. The above results were reviewed and recommended by the Audit Committee, for approval by the Board, at its Meeting held on May 15, 2023 and were approved and taken on record at the Meeting of the Board of Directors of the Company held on that date. 2. The financial results of the Company have been prepared in accordance with Indian Accounting Standards (‘Ind AS”) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time). 3. The financial results for the year ended March 31, 2023 have been audited by the statutory auditors of the Company. The audit report does not contain any modifications. The audit report will be filed with the Stock Exchanges and will also be available on the Company’s website - www.pfizerltd.co.in 4. Figures for the quarter ended March 31, 2023 and March 31, 2022 represent the difference between the audited figures in respect of the full financial year and published unaudited figures of nine months ended December 31, 2022 and December 31, 2021 respectively which were subject to a limited review by the statutory auditors. 5. Net exceptional items aggregating Rs 33.00 crore for the year ended March 31, 2023 includes: a. Income of Rs 67.12 crore on account of sale of Business undertaking at Thane together with its related business assets and liabilities during the quarter ended March 31, 2023. b. Charge of Rs 86.71 crore on account of re-evaluation and reassessment of the risk relating to the Company’s old pending VAT / CST litigations, during the quarter ended March 31, 2023. c. Income of Rs 188.92 crore on account of transfer of certain primarily off patented and generic established medicines business (Upjohn Business) as a going concern together with its related business assets and liabilities during the quarter ended September 30, 2022. d. Charge of Rs 129.85 crore on account of Voluntary Retirement Scheme (VRS) and an additional charge of Rs 6.48 crore (net) on account of restructuring to drive business transformation during the quarter ended June 30, 2022. 6. The Company has only one segment which is ‘Pharmaceuticals’. Therefore, disclosure relating to segments is not applicable and accordingly not made. 7. The Board of Directors at their meeting held on September 6, 2022 had declared an interim (Special) dividend of Rs. 30 per equity share of Rs. 10 each (300%) for the financial year ending March 31, 2023 in view of the gain on account of sale of Upjohn business. The said interim (Special) dividend was paid on September 30, 2022. In addition to the above, the Board of Directors has further at its Meeting held today, recommended a final dividend of Rs. 35 per equity share of `10 each (350%) and a special dividend of Rs. 5 per equity share of Rs. 10 each (50%), in view of the gain on sale of business undertaking at Thane, totaling to a dividend of Rs. 40 per equity share of Rs. 10 each (400%) for the financial year ended March 31, 2023. The aggregate dividend for the financial year ended March 31, 2023 including the interim (Special) dividend paid on September 30, 2022, amounts to Rs. 70 per equity share of Rs. 10 each (700%). 8. Figures for previous quarters / year have been regrouped / restated where necessary. Single segment 2022-04-01 2023-03-31 Audited Standalone 24247600000.00 1010500000.00 25258100000.00 3452700000.00 4719200000.00 564800000.00 3316800000.00 133900000.00 1055100000.00 4105500000.00 17348000000.00 7910100000.00 330000000.00 8240100000.00 2518200000.00 -517400000.00 2000800000.00 0.00 6239300000.00 0.00 0.00 0.00 0.00 6239300000.00 36100000.00 6275400000.00 0.00 0.00 457500000.00 10 0.00 136.38 136.38 0.00 0.00 136.38 136.38 Other Expenses 1094500000.00 Other Expenses 4105500000.00 1775300000.00 79300000.00 0.00 5274900000.00 442300000.00 0.00 0.00 0.00 0.00 0.00 0.00 130200000.00 130200000.00 976700000.00 6077700000.00 14756400000.00 4177000000.00 0.00 1517300000.00 366000000.00 18229200000.00 0.00 643900000.00 20756400000.00 0.00 0.00 24933400000.00 317500000.00 40007300000.00 457500000.00 31615500000.00 32073000000.00 32073000000.00 0.00 0.00 933200000.00 933200000.00 427600000.00 0.00 0.00 0.00 1360800000.00 25000000.00 2170600000.00 1021300000.00 3216900000.00 743600000.00 1005200000.00 1607800000.00 0.00 6573500000.00 0.00 0.00 7934300000.00 40007300000.00 0.00 218500000.00 -102000000.00 0.00 733800000.00 0.00 0.00 0.00 0.00 -381100000.00 0.00 -294000000.00 0.00 1055140000.00 0.00 -520110000.00 0.00 0.00 0.00 0.00 0.00 854900000.00 127040000.00 0.00 0.00 0.00 0.00 313400000.00 0.00 295770000.00 8535870000.00 0.00 0.00 0.00 3025800000.00 -1953100000.00 3556970000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 12200000.00 649800000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 711100000.00 0.00 -434000000.00 0.00 -360500000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 352000000.00 2972100000.00 127500000.00 0.00 -6300000.00 -3457900000.00 -261430000.00 0.00 -261430000.00 0.00 -261430000.00 56100000.00 48300000.00 14200000.00 12200000.00 0.00 0.00